Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease

Inclusion Criteria: * The patient must have successfully completed the full 78-week duration of the double-blind CL-758007 study. * Male or female (age 50 years and older): Female must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal). * Patient must be living in the community with a reliable caregiver. Participant living in an assisted living facility may be included if study medication intake is supervised and participant has a reliable caregiver. * The patient must be presenting a reasonably good nutritional status. * Signed inform consent from the patient or legal representative. Exclusion Criteria: Patients will not be eligible to participate in the study if they meet any of the following criteria: * The patient participates in another drug trial during the study. * The patient with a clinically significant and/or uncontrolled condition or other significant medical disease. * The patient is unable to swallow medication tablets.